Conference Expired

MEEGID 2025 : 17th International Conference on Molecular Epidemiology and Evolutional Genetics of Infectious Diseases

In Person India November 18-21, 2025
Visit Website

About the Conference

Organized by Elsevier, the 17th International Conference on Molecular Epidemiology and Evolutionary Genetics of Infectious Diseases (MEEGID XVII) will include 10 – 15 plenary lectures, 15 – 20 two-hour specialized symposia, and several poster sessions. Special emphasis will be given to health problems of specific interest to the present world: COVID-19, the spread of transmissible diseases linked to climate and ecological disorders, tuberculosis, AIDS, malaria, to name a few.

Plenary lectures and symposia will also deal with transversal topics, such as population genetics, evolution, speciation, taxonomy, phylogenetics and phylodynamics, modelling, and molecular epidemiology.

Attending this conference will enable you to learn about the latest developments in infectious diseases and epidemiology research from experts in the field, present your latest research to your peers and network with an interdisciplinary group from around the world - including academics and researchers, as well as health and industry professionals.

Oral and poster abstracts are invited on the following topics and should be submitted using the online abstract submission system https://auth.oxfordabstracts.com/?redirect=/stages/76927/submitter

Deadline: 30 May 2025

Conference Topics:

Genetics and genomics of pathogens and vectors
Host-pathogen Interactions
Host susceptibility to transmissible diseases
Molecular epidemiology and taxonomy
Population genetics and genomics
Phylogenetics, phylogenomics, phylogeography
Metagenomics
Evolution of resistance and response to immune system pressures
Experimental evolution
Mathematical modelling of infectious processes
One Health approaches to infectious diseases

Topics of Interest

2 topics

Research papers are invited in, but not limited to, the following areas:

Comments

Share context, clarifications, or discussion about this CFP.

Please sign in to leave a comment. Sign in

No comments yet. Be the first to start the discussion.